| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 04/01/2009 | EP2042517A1 Optimized FC variants and methods for their generation |
| 04/01/2009 | EP2042512A2 Polynucleic acids and proteins from a porcine reproductive and respiratory syndrome virus and uses thereof |
| 04/01/2009 | EP2042509A1 Modulators of the function of FAS receptors and other proteins |
| 04/01/2009 | EP2042196A2 Remodelling and glycoconjugation of Granulocyte Colony Stimulating Factor (G-CSF) |
| 04/01/2009 | EP2042194A2 Treatment of refractory human tumors with epidermal growth factor receptor antagonists |
| 04/01/2009 | EP2042193A1 RNA Vaccines |
| 04/01/2009 | EP2042192A2 Tolerogenic fragments of natural allergens |
| 04/01/2009 | EP2042191A1 Anaplastic Lymphoma Kinase (ALK) as oncoantigen for lymphoma vaccination |
| 04/01/2009 | EP2042187A1 Use of soluble CEACAM8 for diagnosing, treating or monitoring diseases, and a method for screening compounds that prevent apoptosis |
| 04/01/2009 | EP2042186A1 Novel polypeptide ligands for toll-like receptor 2 (TLR2) |
| 04/01/2009 | EP2042161A1 Propellant-free spray composition comprising anti-emetic agent |
| 04/01/2009 | EP2041323A1 Virosomes, methods of preparation, and immunogenic compositions |
| 04/01/2009 | EP2041321A2 Viral inhibitory nucleotide sequences and vaccines |
| 04/01/2009 | EP2041286A2 Process for making oligopeptides |
| 04/01/2009 | EP2041268A2 Application of anti-apoptotic genes expression in mammalian cells for perfusion culture |
| 04/01/2009 | EP2041181A1 Specific protease inhibitors and their use in cancer therapy |
| 04/01/2009 | EP2041180A2 Ilt3 binding molecules and uses therefor |
| 04/01/2009 | EP2041178A2 Single-chain multivalent binding proteins with effector function |
| 04/01/2009 | EP2041177A2 High affinity antibodies to human il-6 receptor |
| 04/01/2009 | EP2040753A2 Progastrin inhibitors in the treatment of colon cancer |
| 04/01/2009 | EP2040751A2 Combination therapy employing lymphotoxin beta receptor binding molecules in combination with second agents |
| 04/01/2009 | EP2040750A2 Methods and compositions for increasing the efficiency of therapeutic antibodies using gamma delta t cell activators |
| 04/01/2009 | EP2040749A2 Pharmaceutical compositions containing monoclonal anti idiotypic anti-ca-125 antibody and aluminium |
| 04/01/2009 | EP2040748A2 Use of ppd for the adjuvantation of a nucleic acid vaccine |
| 04/01/2009 | EP2040747A2 Soluble stabilized trimeric hiv env proteins and uses thereof |
| 04/01/2009 | EP2040745A2 Expanding the t cell repertoire to include subdominant epitopes by vaccination with antigens delivered as protein fragments or peptide cocktails |
| 04/01/2009 | EP2040744A2 Live vaccine strains of francisella |
| 04/01/2009 | EP2040743A2 Vaccines for malaria |
| 04/01/2009 | EP2040742A2 Vaccines for malaria |
| 04/01/2009 | EP2040730A2 Modulation of nkg2d |
| 04/01/2009 | EP1917032B1 Use of a botulinum toxin to improve gastric emptying and/or to treat gerd |
| 04/01/2009 | EP1879612B1 Use of native peptides and their optimized derivatives for vaccination |
| 04/01/2009 | EP1549341B1 Tissue factor targeted antibodies as anticoagulants |
| 04/01/2009 | EP1472375B1 Gene products differentially expressed in cancerous breast cells and their methods of use |
| 04/01/2009 | EP1467720B1 Dna dosage forms |
| 04/01/2009 | EP1446425B1 Treatment of micro-organism infection |
| 04/01/2009 | EP1439856B1 Recombinant rabies vaccine and methods of preparation and use |
| 04/01/2009 | EP1349873B1 Modulation of il-2- and il-15-mediated t cell responses |
| 04/01/2009 | EP1119623B1 Mage-a3 peptides presented by hla class ii molecules |
| 04/01/2009 | CN101400793A Novel cancer-associated antigen |
| 04/01/2009 | CN101400783A Live attenuated bordetella strains as a single dose vaccine against whooping cough |
| 04/01/2009 | CN101400703A Domain antibody construct |
| 04/01/2009 | CN101400406A Compositions and methods of use for antibodies of Dickkopf-1 and/or -4 |
| 04/01/2009 | CN101400366A Hepatitis c virus non structural fusion protein |
| 04/01/2009 | CN101397574A Flavivirus NS1 subunit vaccine |
| 04/01/2009 | CN101397571A Preparation of double promoter DNA anti-caries vaccine pCN-SSIE |
| 04/01/2009 | CN101397342A Anti-schistosoma japonicum monoclonal antibody NP11-4 chimeric Fab antibody, preparation method and use |
| 04/01/2009 | CN101397336A Antigenic Neisserial peptides |
| 04/01/2009 | CN101397335A Particles of HCV envelope proteins: use for vaccination |
| 04/01/2009 | CN101397334A Anti-human cytomegalovirus gBn1 antibody, preparation method and special antigen |
| 04/01/2009 | CN101397332A Functional peptide section of epididymis protease inhibitors and multiple antigenic peptide constructed thereby |
| 04/01/2009 | CN101396564A Protein capable of adjusting sperm capacitation and use thereof |
| 04/01/2009 | CN101396557A Preparation method of combined attenuated live vaccine of measles, parotitis and rubella |
| 04/01/2009 | CN101396556A Immunoregulation DNA vaccine capable of preventing chicken Eimeria maxima |
| 04/01/2009 | CN100473721C Pneumovirus NS proteins antagonising interferon (IFN) response |
| 04/01/2009 | CN100473664C Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof |
| 04/01/2009 | CN100473417C Method of modulating memory effector T-cells using CD2-binding agent, and compositions |
| 03/31/2009 | US7511124 immunoconjugate and duramycin-based compositions and combinations that bind and inhibit anionic phospholipids and aminophospholipids, for use in the safe and effective treatment of cancer, viral infections and related diseases; kits |
| 03/31/2009 | US7511123 Binding to antigen; controlling concentration |
| 03/31/2009 | US7511122 Monoclonal and chimeric antibodies that bind to lipoteichoic acid of Gram positive bacteria. The antibodies also bind to whole bacteria and enhance phagocytosis and killing of the bacteria in vitro and enhance protection from lethal; light and heavy chains comprising complementarity determining regions |
| 03/31/2009 | US7511121 Polymeric immunoglobulin fusion proteins that target low-affinity Fcγreceptors |
| 03/31/2009 | US7511031 Transcutaneous photodynamic therapy; patch placed over target tissue; liposomal, transdermal, iontophoretic photosensitizing agent; light emitting diodes; atherosclerotic lesions and restenotic lesions |
| 03/31/2009 | US7511027 Administering a nucleoside or a nucleoside analog, such as (5'-fluoro-5-methyl-beta-arabinofuranosyl-uridine) or salt or prodrug that suppresses the expression of hepatitis B surface or preS1 antigen in the host 100-fold |
| 03/31/2009 | US7511017 Inhibiting apoptosis associated with HIV infection; immunoglobulin constant domain heterologous polypeptide; isolated nucleic acid encoding a human polypeptide, tumor necrosis factor receptor-5 |
| 03/31/2009 | US7510875 Methods for producing purified adenoviral vectors |
| 03/31/2009 | US7510863 Nucleotide sequence coding single stranded RNA viral sequences for use in generation antibodies to prevent, treat and diagnose respiratory system disorders in poultry; veterinary medicine |
| 03/31/2009 | US7510862 Nucleic acid comprising retroviral sequences for use as tools in generation of vaccines for prevention of viral diseases and infection; immunotherapy; viricides, antisense agents |
| 03/31/2009 | US7510855 Comprises nucleotide sequences coding protein of urogenital system for identifying moduators for treatment of cell proliferative and metastatic disorders |
| 03/31/2009 | US7510853 Exhibiting similarity to cytokine; isolated or recombinant polynucleotide encoding antigenic polypeptide of sequence 2 |
| 03/31/2009 | US7510848 Enzyme resistance; chromatography; bovine spongiform encephalopathy; detecting and separating from whole blood sample, prion protein bound to binding material,wherein the polymeric prion protein binding material comprises an aminated, sulfonated, butylated, or arylated polymethacrylate matrix |
| 03/31/2009 | US7510847 Drug screening for compound having uricosuric regulating action by incubating a transformed cell expressing a recombinant protein with uric acid; and determining an uptake of uric acid; gout |
| 03/31/2009 | US7510840 Method of inhibiting growth or survival of a cell by providing an anti-108P5H8 antibody |
| 03/31/2009 | US7510830 Cancer treatment by combination therapy |
| 03/31/2009 | US7510720 Producing a passive immunity vaccine against Sarcocystis neurona by providing Sarcocystis neurona 16 kDa and 30 kDa antigens as determined by SDS polyacrylamide gel electrophoresis;immunizing mammal in mixture with adjuvant; removing serum; isolating antibodies; administering antibodies |
| 03/31/2009 | US7510719 Methods of producing influenza vaccine compositions |
| 03/31/2009 | US7510718 Expression vector comprising nucleotide sequences coding multimeric nuclear anchoring-protein for use as tool in transfer, expression and propagation of heterologous gene sequences |
| 03/31/2009 | US7510717 Non-toxic mutants of pathogenic gram-negative bacteria |
| 03/31/2009 | US7510715 Contacting macrophage or T-cell with an effective amount of a cyclophilin from Toxoplasma or biologically active fragment thereof to inhibit HIV (human immunodeficiency virus) infection of a cell; autoimmune diseases |
| 03/31/2009 | US7510713 Administering monoclonal antibody secific to lymphocyte peripheral membrane protein for treating and preventing transplant rejection, blood, skin, autoimmune, allergic and diabetic disorders |
| 03/31/2009 | US7510712 Administering a monoclonal anti-CD80 antibody or CD80 binding fragment that binds specifically to human CD80 antigen and inhibits binding of the CD80 antigen to CD28 without inhibiting the binding of the CD80 antigen to CTLA-4; immunosuppressants, autoimmune diseases, transplant rejection |
| 03/31/2009 | US7510711 Nucleotide sequence coding monoclonal antibody; anticancer agents; antiinflammatory agents; immunology disorders |
| 03/31/2009 | US7510710 Etomoxir and a 2-deoxy-D-glucose compound; antiinflammatory, antiproliferative, anticarcinogenic and wound healing agents; drug resistant cancers |
| 03/31/2009 | US7510709 Method of treating inflammatory disease by inhibition of IL-17 production |
| 03/31/2009 | US7510708 Disruption of the REG pathway |
| 03/31/2009 | US7510707 PAR, a novel marker gene for breast and prostate cancers |
| 03/31/2009 | US7510698 Adjuvant formulation consisting essentially of a metabolizable oil and alpha tocopherol in emulsion for enhancing immune response to infection |
| 03/31/2009 | CA2494888C Substances for preventing and treating autoimmune diseases |
| 03/31/2009 | CA2210139C Immunogenic conjugate molecules |
| 03/31/2009 | CA2192467C Calcium binding recombinant antibody against protein c |
| 03/29/2009 | CA2704064A1 Humanized antibodies against the .beta.-amyloid peptide |
| 03/28/2009 | CA2640655A1 Anaplastic lymphoma kinase (alk) as oncoantigen for lymphoma vaccination |
| 03/26/2009 | WO2009039388A2 Compositions and methods for detecting and treating ophthalmic disorders |
| 03/26/2009 | WO2009039341A2 Neoepitope detection of disease using protein arrays |
| 03/26/2009 | WO2009039337A2 Inhibition of angiogenesis |
| 03/26/2009 | WO2009039310A2 Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment |
| 03/26/2009 | WO2009039256A1 Growth factor fraction compositions and methods |
| 03/26/2009 | WO2009039246A2 Methods of treating a flaviviridae family viral infection, compositions for treating a flaviviridae family viral infection, and screening assays for identifying compositions for treating a flaviviridae family viral infection |
| 03/26/2009 | WO2009039178A1 Immunogenic formulation |
| 03/26/2009 | WO2009039175A2 Method for inhibiting bone resorption |
| 03/26/2009 | WO2009038770A2 Detoxified recombinant botulinum neurotoxin |